The primary therapeutic function of this combination supplement is relevant for easing symptoms and conditions resulting from a lack of calcium and Vitamin D, focusing on skeletal and neuromuscular health. Maintaining adequate intake of calcium and Vitamin D is commonly used to help with supporting bone strength.

This supplement is commonly used to help with deficiency states where hypocalcemia (low blood calcium), Vitamin D deficiency, or conditions like osteoporosis, osteomalacia, or rickets are relevant. It is generally applied in contexts where additional symptomatic support is needed to address systemic imbalance.

“The supplement provides support that helps ease the overall symptom burden associated with low calcium levels.”

It may assist with slowing the rate of bone mineral loss and supports the management of fracture risk in older adults. Furthermore, it is relevant for easing symptoms that interfere with daily functioning, such as muscle cramps and weakness, particularly during high-demand phases like pregnancy and breastfeeding.

---

Quick Fact: Relief for Muscular Spasms The supplement is commonly used to help with involuntary muscle cramps and spasms that arise from mineral deficits, helping to support general well-being during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

Who Can and Cannot Use Shelcal-500?

The eligibility for Shelcal-500 (Calcium Carbonate and Cholecalciferol) is strictly defined by regulatory documents, focusing on existing medical conditions that relate to mineral balance and organ function.

Absolute Contraindications (Must Not Use):

• Hypercalcaemia (high blood calcium levels), Hypercalciuria, or Hypervitaminosis D (Vitamin D overdose).
• Severe Renal Impairment and established Nephrolithiasis (kidney stones).
• Hypersensitivity to the active ingredients or excipients.

---

Conditional and Restricted Use:

• Renal Impairment: Contraindicated in severe cases. Mild to moderate cases require caution and monitoring of calcium levels.
• Sarcoidosis and Immobilized Patients with Osteoporosis require caution and medical supervision due to an increased risk of hypercalcaemia.
• Pediatric Use: Generally indicated for adults. Use in children and adolescents is often not recommended or requires specific dose monitoring, and some formulations are contraindicated in those under 18 years.

---

Pregnancy and Lactation Eligibility:

Use is permitted to correct confirmed deficiency, but total daily intake of both calcium and Vitamin D from all sources must not exceed official upper limits established to prevent fetal risk. Use during breastfeeding is permitted with monitoring of the infant.

Interactions with other medicines and products

The official regulatory profile for this combination of Calcium Carbonate and Cholecalciferol documents two primary types of interactions: pharmacokinetic interference and pharmacodynamic alteration.

Pharmacokinetic interactions are centered on the calcium component, which can reduce the systemic exposure of several co-administered oral medicines by hindering their absorption. This interference necessitates mandatory timing separation rules for drugs such as quinolone and tetracycline antibiotics, levothyroxine, bisphosphonates, and sodium fluoride. These must be administered at least two to six hours apart, depending on the specific medicine, to ensure their intended efficacy. Furthermore, systemic corticosteroids are officially documented to reduce the body's absorption of calcium.

Pharmacodynamic interactions relate to the effects on calcium levels. Co-administration with thiazide diuretics reduces calcium excretion, carrying an official risk of hypercalcaemia (high blood calcium levels). Elevated calcium levels may also increase the toxicity of cardiac glycosides, requiring close monitoring. Other documented interactions include enzyme-inducing medicines like rifampicin and phenytoin, which can accelerate Vitamin D3 metabolism, thereby reducing its activity. To maintain proper absorption, the supplement must not be taken within two hours of consuming foods high in phytic acid or oxalic acid.

Shelcal-500 operates through the combined pharmacodynamic actions of calcium carbonate and cholecalciferol (Vitamin D3). Upon ingestion, calcium carbonate dissociates into elemental calcium ions (Ca^2+) in the acidic gastric environment. These calcium ions are primarily absorbed in the small intestine via both active transcellular transport and passive paracellular diffusion.

Concurrently, cholecalciferol, a secosteroid, undergoes two-step hydroxylation: first in the liver by 25-hydroxylase to calcidiol (25-hydroxyvitamin D), and then in the kidney by 1-alpha-hydroxylase to calcitriol (1,25-dihydroxyvitamin D), the biologically active hormone.

Calcitriol acts as an agonist for the nuclear Vitamin D Receptor (VDR), forming a heterodimer complex with the Retinoid X Receptor (RXR). This complex translocates to the nucleus and binds to specific Vitamin D Response Elements (VDREs) on target genes, promoting transcriptional regulation. Downstream effects include the increased synthesis of intestinal epithelial calcium transport proteins, such as TRPV6 and calbindin-D9k, which facilitates the enhanced active absorption of the elemental calcium ions from the small intestine into the systemic circulation.

This concerted action results in increased plasma calcium and phosphate concentrations, modulating systemic calcium homeostasis. The elevated concentration of Ca^2+ is then made available for its structural and signaling roles across various tissues, including incorporation into the crystalline structure of the mineralized matrix in osseous tissue and participation in cell-signaling cascades in excitable tissues.

How to Use Shelcal-500: Official Administration Guidelines

Shelcal-500 (Calcium Carbonate and Cholecalciferol) is supplied as an oral tablet and is used according to specific instructions. The proper administration protocol focuses on optimal timing and frequency to ensure effective absorption of the active components.

---

Official Dosing and Administration

The following high-level guidance summarizes the use of this combination product.

Feature	Official Labeled Instruction
Route of Administration	Oral use only.
Dosing Schedule	Typically once or twice daily for maintenance, providing the standard 500 mg elemental calcium dose. Higher daily doses may be prescribed for deficiency support.
Timing in Relation to Meals	Must be taken with food or immediately following a meal to maximize the intestinal absorption of the calcium component.
Preparation	Tablets should be swallowed whole with a full glass of water. If chewable, the tablet must be chewed or sucked.

---

Procedural and Population Rules

Specific protocols are established for maintaining a consistent schedule and addressing special populations.

• Dose Division: When total elemental calcium intake is high, the daily dose should be divided and spaced across the day. This is a procedural requirement to optimize uptake.
• Missed Dose Protocol: If a scheduled dose is forgotten, it should be taken when remembered, unless it is close to the time for the next dose, in which case the missed dose must be skipped (doses should never be doubled).
• Population Note: No dose adjustment is required for patients with hepatic impairment. However, use is generally restricted or contraindicated in severe renal impairment.

Research evidence / Overview of Studies for Calcium Carbonate and Cholecalciferol

Evidence for Deficiency Correction and Bone Mineralization Support

Research has consistently was studied for its effect in individuals with confirmed low nutrient status. The main scientific efforts involve Randomized Controlled Trials (RCTs) and systematic reviews where scientists monitored changes in key biomarkers. Specifically, research examined serum levels of 25-hydroxyvitamin D, which is the standard measure of Vitamin D status, and other outcomes related to systemic or functional imbalance like Parathyroid Hormone (PTH) and overall calcium metabolism.

Findings describe patterns observed in the studies where supplementation was associated with measurements showing shifts in low baseline levels of vitamin D and calcium biomarkers over short- to intermediate-term observation periods. Studies report how symptoms evolved in populations with deficiency-related bone softening (osteomalacia or rickets), describing changes in radiographic and clinical measurements. What remains uncertain is the exact duration of use necessary to sustain measured biomarker levels over long periods for all individuals.

---

Evidence for Bone Mineral Density Maintenance

Intermediate-term research, including studies observing responses over defined time intervals like one to three years, was studied for its impact on Bone Mineral Density (BMD). Research examined changes in bone density measurements at skeletal sites like the hip and spine, typically in postmenopausal women and older adults. These studies monitored BMD using specialized imaging.

Studies report how symptoms evolved related to BMD measurements, which were often small and primarily observed during the initial year of the study. Findings describe patterns observed in the studies that suggest patterns related to the preservation or slowing of bone mineral density change in some groups. However, the reported size of the observed change in BMD measurements may be modest, and findings were mixed when compared across different study populations.

---

Evidence for Fracture Risk and Outcome Tracking

Large-scale, long-term Randomized Controlled Trials (RCTs) were evaluated in older adults to assess fracture incidence. These studies monitored the occurrence of specific fracture events, such as hip and non-vertebral fractures, over observation periods lasting several years, often in community-dwelling and institutionalized elderly individuals.

Studies report how symptoms evolved regarding fracture incidence, but the findings were mixed depending on the population examined. Data show patterns related to reduced fracture incidence in specific high-risk groups, such as those living in institutional settings or those who were significantly deficient at the start of the study. Conversely, large studies involving generally healthier, community-dwelling older adults often reported measurements that did not indicate a clear difference from control groups.

Key Studies & References

1. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force Recommendation Statement (2013)
2. The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women (Used for adjunctive context)

Common questions about Shelcal-500 (FAQ)

---

Q: Is Shelcal-500 safe for long-term daily use?

Official information indicates that if this product is used in long-term treatment, monitoring may be necessary. Regulatory labels state that monitoring serum calcium levels (calcium in the blood) and assessing kidney function (by measuring serum creatinine) may be required. The duration of treatment is generally determined by the specific therapeutic goal being addressed.

Q: Can Shelcal-500 be crushed or dissolved for easier swallowing?

Official product information specifies the administration method for the tablets. Standard tablets are officially recommended to be swallowed whole with a full glass of water. If the specific product is formulated as a chewable or effervescent tablet, the preparation should be used according to those specific dosage form instructions (e.g., chewed, sucked, or dissolved).

Q: Can Shelcal-500 interact with my multivitamin?

Regulatory information advises caution regarding other sources of calcium and alkali. This is because the overall total amount of calcium and Vitamin D from all sources, including dietary supplements like a multivitamin, must be taken into consideration. The healthcare provider who prescribed or recommended this product generally monitors the patient's total nutrient intake.

Q: How should Shelcal-500 be properly disposed of?

When disposing of unused or expired Shelcal-500, disposal should be handled according to local requirements for unused medicine. According to official guidelines, the medicine should not be thrown away via wastewater systems or with your regular household waste to protect the environment.

How to Store and Dispose of Shelcal-500

The storage and disposal of Shelcal-500 must strictly adhere to regulatory labeling to maintain product stability and ensure safety.

---

Official Storage Requirements

The medicine must be stored at or below 25°C (room temperature) in a cool and dry place. It is essential to protect the tablets from excessive heat, moisture, and direct light. Always store the tablets in their original container and ensure it is kept tightly closed.

A mandatory requirement is to keep this medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Shelcal-500 should be disposed of according to local regulations as specified in official documents. To protect the environment, do not throw away any medicines via wastewater or household waste unless specifically authorized to do so.